Wed, Jul 23, 2014, 9:58 AM EDT - U.S. Markets close in 6 hrs 2 mins

Recent

% | $
Click the to save as a favorite.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Jan 10, 2013 12:17 AM Flag

    NCCN Annual conference schedule posted

    $$$$

    I know it's always a stretch, but I figured to post it and let the interested parties sort it out.
    Here's the stuff I think may interest this MB...there's lots more at the NCCN website.

    3/14/12 11:20 AM – 12:00 PM
    New Developments in Thyroid Cancer
    Robert I. Haddad, MD
    Dana-Farber/Brigham and Women's Cancer Center

    3/14/12 1:15 – 2:30 PM
    New Developments in the Management of Prostate Cancer
    Philip W. Kantoff, MD
    Dana-Farber/Brigham and Women's Cancer Center
    James L. Mohler, MD
    Roswell Park Cancer Institute

    Keep in mind...Dr Kantoff published some Cabo data in the Nov edition of JNCCN..about 2 weeks prior to the mCRPC P2 JCO publication. I wouldn't rule out some discussion in this forum, particularly w/ EXEL's announcement of moving into a pivotal pre-chemo trial w/ Zytiga.

    March will be a busy month in FLA for cancer research. The week prior, Dr Jose Baselga of Mass General is presenting at the 30th Miami BC Symposium on emerging treatments in late stage HER+ BC. This may be a likely forum for some interim reporting on the Dr Michaela Higgins (PI) trial. This trial has been recruiting for over a year w/ a primary endpoint of bone scan response...so, if enrollment has gone well, I suspect we could see some early BSR data.

    GLTA

 
EXEL
3.697+0.108(+2.99%)9:58 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.